Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7458+0.0176 (+2.42%)
At close: 04:00PM EDT
0.7001 -0.05 (-6.13%)
After hours: 07:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7282
Open0.7500
Bid0.7001 x 1000
Ask0.7500 x 3000
Day's Range0.7200 - 0.7800
52 Week Range0.6100 - 2.3180
Volume161,956
Avg. Volume303,701
Market Cap56.849M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.5040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • GlobeNewswire

    Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

    - HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - - Four-Month, Three Arm Trial will Inform on Numerous NASH Functional Biomarkers - EDISON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treat

  • GlobeNewswire

    Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

    EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time. The virtual presentation will be broa

  • GlobeNewswire

    Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia

    - Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in Asia - EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular c

Advertisement
Advertisement